In 2026, Zepbound's civilian coverage map became a mosaic, but the military pharmacy was less complicated: If you met the criteria, route the fill properly, and the most effective weight loss injection around was covered.

Yes, TRICARE will provide access to Zepbound in 2026 with prior authorization, for both of its FDA-approved indications: moderate to severe obstructive sleep apnea in adults with obesity, and chronic weight management (BMI ≥ 30 or ≥ 27 with a weight-related condition). Express Scripts authorizes the authorization; documentation of lifestyle modification is expected for the weight indication, and an OSA route is anchored by a sleep study. Like other GLP-1s, this is not typically available in military pharmacies; home delivery is approximately $38 per 90 days, and retail is approximately $43 per 30 days.

This is what changes this summer with the two-indication strategy, the channel playbook, costs by beneficiary category, and the TRICARE For Life coordination.

Two Covered Indications, Two Different Files

The weight-management route mirrors the FDA label guidance TRICARE used to follow for anti-obesity drugs: BMI of 30 or higher qualifies alone, 27 to 29.9 qualifies with a weight-related condition (such as hypertension, dyslipidemia, type 2 diabetes or sleep apnea) and documented lifestyle-modification efforts (counseling notes are acceptable) and renewals are based on meaningful weight loss from baseline (usually the 5 percent standard).

The sleep apnea path is based on other evidence. The FDA approval of Zepbound for moderate to severe OSA in adults with obesity in December 2024 shifted the sleep study-confirmed diagnosis to the top of the pile, and CPAP history became an additional asset. If both a qualifying weight and OSA are present, the beneficiary should provide whichever file has the best objective sleep study, which may be the OSA file. 

The Channel Playbook for Military Families

Formulary drugs are available at military treatment facility pharmacies free of charge, but they are not always on hand, so call first before relying on the $0 channel for the weight-loss GLP-1. The workhorse is TRICARE Pharmacy Home Delivery, which ships 90-day supplies of formulary brands at about $38 per shipment (or $13 per month), consistently. Retail network pharmacies take around $43 to fill, if speed is crucial.

Active duty service members are exempt from paying all copays on all covered medication per channel, while family members and retirees will pay the copays (which change on an annual basis in accordance with TRICARE's channel schedule, found on TRICARE's pharmacy page). When a copy of the prescription is transferred, the prescription does not restart the paperwork, but rather continues where it left off using prior authorizations. 

TRICARE For Life: The July 2026 Change

 Military retirees who are Medicare eligible coordinate benefits and Medicare Part D will pay first when enrolled. The pilot to address the Zepbound KwikPen for weight management through the Medicare GLP-1 Bridge program will be implemented starting July 1, 2026, and will run through December 2027, with a copayment of $50 per month capped at the $245 federal price, according to NPR. Currently, Part D already covers the OSA indication.

Currently, members of the TFL should be collecting starting-weight records as this will help maintain the Bridge status even if the weight has dropped off later if the prescriber attests that you met criteria at therapy start. For all cases, TRICARE covers secondary, which usually leaves little to no out-of-pocket expenses.

Denials, Appeals, and the Self-Pay Bridge

Typical denial reasons for TRICARE Zepbound claims involve the lack of a BMI or a lack of evidence of comorbidity, lack of lifestyle modification evidence, or lack of a sleep study. Please correct the named item and resubmit; Express Scripts takes care of completed files in days. Documented cases caught up in the appeal process via Express Scripts and TRICARE's appeal process.

Paperwork resolves, but LillyDirect single dose vials at $349 (2.5 mg starter) to $499 per month, KwikPens at $399 to $449, federal TrumpRx channel as it phases-in near $346. All of it is more cheap than a covered TRICARE fill at $13 to $43 per month, so think of cash as a temporary solution. 

Frequently Asked Questions

Yes, with prior authorization requiring a BMI of 30 or higher, or 27 to 29.9 with a weight-related condition, plus lifestyle-modification documentation. Renewals require meaningful weight loss from baseline. Express Scripts processes requests within days when files are complete, and the authorization follows your prescription across fill channels.

Yes. Following the December 2024 FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity, a sleep-study-confirmed diagnosis anchors the prior authorization, with CPAP history strengthening the file. Beneficiaries qualifying under both indications should submit the stronger file; the objective sleep study often clears fastest.

Active duty members pay $0 at all channels. Retirees and family members pay about $38 per 90-day home delivery supply (roughly $13 monthly) or about $43 per 30 days at retail network pharmacies. Military pharmacies are free when they stock it, which is uncommon for weight-loss GLP-1s.

Yes, coordinated with Medicare. The OSA indication is coverable under Part D today, and the Medicare GLP-1 Bridge pilot adds weight-management coverage of the Zepbound KwikPen from July 1, 2026 with $50 monthly copay caps. TRICARE wraps secondary, typically minimizing what's left.

Both are covered with similar criteria, so the choice is clinical, made with your prescriber. Zepbound's dual-hormone mechanism produced greater average weight loss in head-to-head trials, while Wegovy carries the cardiovascular risk-reduction approval relevant to heart patients. Whichever you start, document everything; a failed trial of one strengthens any later switch.